Ask HopeStage to review this study with me
Study ID: NCT07565428. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT07565428
Roluperidone for schizophrenia
This study is recruiting in the United States. It is testing roluperidone for schizophrenia.
SchizophreniaOtherFrom 18 Years to 55 Years
Key information made simple
What is this study testing?
This study is testing whether Roluperidone may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Roluperidone, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in United States.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a research setting, with sites including CBH Health, LLC dba CenExel in Gaithersburg and Hassman Research Institute, LLC dba CenExel in Marlton. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: April 23, 2026
- Recruitment status
- Recruiting
- Estimated enrollment
- Not clearly listed
- Sponsor
- Minerva Neurosciences
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07565428
- Official title
- Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT07565428. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Minerva Neurosciences, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT07459647
A Long-Term Study of ML-007C-MA in Adults With Schizophrenia
This study is recruiting in the United States. It is testing ML-007C-MA for schizophrenia.
RecruitingISRCTN44297014
A phase III active comparator-controlled study to study the safety and efficacy of lurasidone in subjects with schizophrenia (PEARL 3 extension study)
This study is recruiting in the United States, in Colombia, in Germany, .... It focuses on schizophrenia.
RecruitingISRCTN16838597
A phase three study to study the safety and efficacy of three doses of lurasidone hydrochloride (HCl) in acutely psychotic people with schizophrenia
This study is recruiting in the United States, in France, in the United Kingdom, .... It focuses on schizophrenia.